Epigenetic Enzymes Are Replaced in Atherogenesis and Regulatory T Cell Conversion by Groups of Upregulated Enzymes

Ying Shao,Valeria Chernaya,Hong Wang,Xiao-feng Yang

DOI: https://doi.org/10.1096/fasebj.29.1_supplement.877.14

2015-01-01

Abstract:Epigenetic enzymes play essential roles not only in cellular differentiation and organ development, but also in the pathogenesis of diseases. However, the global profiling of tissue expressions and dynamic changes of those enzymes remain unknown. Using the NIH‐UniGene experimental database mining, we examined the tissue expression profiles and pathophysiological responses of 164 epigenetic enzymes. The following important findings were made: 1) heart, liver, lymph node and thymus are among the tissues in which there are large numbers of HAT, HDAC, HMT, and HDM with high expression levels, while there are low numbers of these enzymes in tissues such as vessels; 2) In several diseases and pathophysiological statuses, such as atherosclerosis, type II diabetes, programmed necrosis, and the conversion of effector T cells to regulatory T cells, most of the epigenetic enzymes with significant expression changes are enzymes with low expression levels in target tissues/cells; and 3) the tissue expression levels of some HMT, HDM and other enzymes are positively correlated with the tissue global methylation index, which suggests a new regulatory hierarchy of methylation in epigenetic machinery. Taken all together, for the first time our results have demonstrated that the expression levels of epigenetic enzymes are highly tissue‐specific. In response to the changes of pathophysiological statuses and diseases, the epigenetic enzymes that function physiologically are replaced by the groups of enzymes that are significantly upregulated in pathological conditions. Mechanistically, the expression changes of epigenetic enzymes can be partially mediated by cellular methylation statuses.